Showing results (11-20 of 36) with videos related to
Sort By:
Pageof 4
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|June 4, 2009
Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiencyRichard L Wasserman, Joseph A Church, Hans H Peter, et al.Clinica Chimica Acta; International Journal of Clinical Chemistry|July 15, 2006
Severe systemic immune response syndrome, low plasma paraoxonase activity, and a new albumin species in a traumatized patient with Gaucher's diseaseDavid Bar-Or, Leonard T Rael, Raphael Bar-Or, et al.Journal of Child and Adolescent Psychopharmacology|February 19, 2021
Evaluation of Intravenous Immunoglobulin in Pediatric Acute-Onset Neuropsychiatric SyndromeIsaac Melamed, Roger H Kobayashi, Maeve O'Connor, et al.Journal of Clinical Immunology|May 11, 2010
Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiencyJohn B Hagan, Mary B Fasano, Sheldon Spector, et al.Immunotherapy|July 29, 2016
Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: long-term efficacy, safety and tolerabilityRichard L Wasserman, Isaac Melamed, Lisa Kobrynski, et al.Clinical Pharmacokinetics|May 11, 2011
Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiencyRichard L Wasserman, Isaac Melamed, Robert P Nelson, et al.Journal of Clinical Immunology|June 22, 2016
Efficacy, Safety, and Pharmacokinetics of a New 10 % Liquid Intravenous Immunoglobulin Containing High Titer Neutralizing Antibody to RSV and Other Respiratory Viruses in Subjects with Primary Immunodeficiency DiseaseRichard L Wasserman, William Lumry, James Harris, et al.Immunotherapy|May 6, 2021
Treatment of children with primary immunodeficiencies with a subcutaneous immunoglobulin 16.5% (cutaquig® [octanorm])Roger H Kobayashi, Jose Fernando Mandujano, Syed M Rehman, et al.Journal of Clinical Immunology|September 2, 2016
Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North AmericaDaniel Suez, Mark Stein, Sudhir Gupta, et al.The Journal of Allergy and Clinical Immunology|August 1, 2012
Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiencyRichard L Wasserman, Isaac Melamed, Mark R Stein, et al.Pageof 4